Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

NCT01198158 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

77

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v7
Stage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Everolimus
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)